NO328245B1 - Ekstrakter av Tanacetum parthenium og farmasoytiske og kosmetiske sammensetninger inneholdende ekstraktene. - Google Patents
Ekstrakter av Tanacetum parthenium og farmasoytiske og kosmetiske sammensetninger inneholdende ekstraktene. Download PDFInfo
- Publication number
- NO328245B1 NO328245B1 NO20015867A NO20015867A NO328245B1 NO 328245 B1 NO328245 B1 NO 328245B1 NO 20015867 A NO20015867 A NO 20015867A NO 20015867 A NO20015867 A NO 20015867A NO 328245 B1 NO328245 B1 NO 328245B1
- Authority
- NO
- Norway
- Prior art keywords
- extracts
- polar solvent
- extract
- lactones
- extracting
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 49
- 241000602316 Tanacetum parthenium Species 0.000 title claims abstract description 16
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 title claims abstract description 15
- 235000008384 feverfew Nutrition 0.000 title claims abstract description 14
- 239000000203 mixture Substances 0.000 title claims description 11
- 239000002537 cosmetic Substances 0.000 title claims description 5
- 239000011347 resin Substances 0.000 claims abstract description 16
- 229920005989 resin Polymers 0.000 claims abstract description 16
- BUQLXKSONWUQAC-UHFFFAOYSA-N Parthenolide Natural products CC1C2OC(=O)C(=C)C2CCC(=C/CCC1(C)O)C BUQLXKSONWUQAC-UHFFFAOYSA-N 0.000 claims abstract description 15
- KTEXNACQROZXEV-PVLRGYAZSA-N parthenolide Chemical compound C1CC(/C)=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]21 KTEXNACQROZXEV-PVLRGYAZSA-N 0.000 claims abstract description 15
- 229940069510 parthenolide Drugs 0.000 claims abstract description 15
- 125000000457 gamma-lactone group Chemical group 0.000 claims abstract description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 10
- 239000012454 non-polar solvent Substances 0.000 claims description 8
- 229930195733 hydrocarbon Natural products 0.000 claims description 7
- 150000002430 hydrocarbons Chemical class 0.000 claims description 7
- 239000004215 Carbon black (E152) Substances 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 6
- 239000000969 carrier Substances 0.000 claims description 6
- 230000001476 alcoholic effect Effects 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 150000001298 alcohols Chemical class 0.000 claims description 4
- 238000001704 evaporation Methods 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims description 3
- 241000196324 Embryophyta Species 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 150000007513 acids Chemical class 0.000 claims description 2
- 230000008020 evaporation Effects 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 239000002798 polar solvent Substances 0.000 claims description 2
- 230000000144 pharmacologic effect Effects 0.000 abstract description 6
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 4
- 238000010828 elution Methods 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 11
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 8
- 239000000006 Nitroglycerin Substances 0.000 description 8
- 229960003711 glyceryl trinitrate Drugs 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
- 229930009674 sesquiterpene lactone Natural products 0.000 description 4
- 150000002107 sesquiterpene lactone derivatives Chemical class 0.000 description 4
- 208000019695 Migraine disease Diseases 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- OIQSGZWRLLAFNQ-UHFFFAOYSA-N 5,6-dihydroxy-3,7-dimethoxy-2-(4-methoxyphenyl)chromen-4-one Chemical compound C1=CC(OC)=CC=C1C1=C(OC)C(=O)C2=C(O)C(O)=C(OC)C=C2O1 OIQSGZWRLLAFNQ-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000000834 fixative Substances 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 150000002212 flavone derivatives Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 210000000627 locus coeruleus Anatomy 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- HRYLQFBHBWLLLL-UHFFFAOYSA-N (+)-costunolide Natural products C1CC(C)=CCCC(C)=CC2OC(=O)C(=C)C21 HRYLQFBHBWLLLL-UHFFFAOYSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- JTXMVXSTHSMVQF-UHFFFAOYSA-N 2-acetyloxyethyl acetate Chemical compound CC(=O)OCCOC(C)=O JTXMVXSTHSMVQF-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- CUGKULNFZMNVQI-UHFFFAOYSA-N Costunolid I Natural products CC1=CCC=C(/C)CCC2C(C1)OC(=O)C2=C CUGKULNFZMNVQI-UHFFFAOYSA-N 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 108700002232 Immediate-Early Genes Proteins 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 241000404133 Leucanthemum Species 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010027603 Migraine headaches Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 1
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
- VQXSOUPNOZTNAI-UHFFFAOYSA-N Pyrethrin I Natural products CC(=CC1CC1C(=O)OC2CC(=O)C(=C2C)CC=C/C=C)C VQXSOUPNOZTNAI-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002460 anti-migrenic effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- JNHKVMWTQCZYHK-CVZWCJCVSA-N artemorin Chemical compound C1CC(=C)[C@H](O)CCC(/C)=C/[C@H]2OC(=O)C(=C)[C@@H]21 JNHKVMWTQCZYHK-CVZWCJCVSA-N 0.000 description 1
- JNHKVMWTQCZYHK-TYESOUJZSA-N artemorin Natural products O=C1C(=C)[C@H]2[C@@H](O1)/C=C(/C)\CC[C@@H](O)C(=C)CC2 JNHKVMWTQCZYHK-TYESOUJZSA-N 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- HRYLQFBHBWLLLL-AHNJNIBGSA-N costunolide Chemical compound C1CC(/C)=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]21 HRYLQFBHBWLLLL-AHNJNIBGSA-N 0.000 description 1
- MMTZAJNKISZWFG-UHFFFAOYSA-N costunolide Natural products CC1CCC2C(CC(=C/C=C1)C)OC(=O)C2=C MMTZAJNKISZWFG-UHFFFAOYSA-N 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000002027 dichloromethane extract Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 229930000731 eudesmanolide Natural products 0.000 description 1
- 150000000551 eudesmanolide derivatives Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229940001448 feverfew extract Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229930002882 germacranolide Natural products 0.000 description 1
- 150000003073 germacranolide derivatives Chemical class 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 150000004273 guaianolide derivatives Chemical class 0.000 description 1
- 239000002035 hexane extract Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 150000002596 lactones Chemical group 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 229930003658 monoterpene Natural products 0.000 description 1
- 125000002299 monoterpene group Chemical group 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229940082615 organic nitrates used in cardiac disease Drugs 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 210000002963 paraventricular hypothalamic nucleus Anatomy 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- HYJYGLGUBUDSLJ-UHFFFAOYSA-N pyrethrin Natural products CCC(=O)OC1CC(=C)C2CC3OC3(C)C2C2OC(=O)C(=C)C12 HYJYGLGUBUDSLJ-UHFFFAOYSA-N 0.000 description 1
- VJFUPGQZSXIULQ-XIGJTORUSA-N pyrethrin II Chemical compound CC1(C)[C@H](/C=C(\C)C(=O)OC)[C@H]1C(=O)O[C@@H]1C(C)=C(C\C=C/C=C)C(=O)C1 VJFUPGQZSXIULQ-XIGJTORUSA-N 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- -1 sesqui-terpene compounds Chemical class 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Birds (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Adornments (AREA)
- Massaging Devices (AREA)
- Cosmetics (AREA)
- Yarns And Mechanical Finishing Of Yarns Or Ropes (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Air Bags (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT1999MI001244A IT1312342B1 (it) | 1999-06-03 | 1999-06-03 | Estratto di tanacetum parthenium sostanzialmente privo di gammalattoni-alfa-insaturi. |
| PCT/EP2000/004976 WO2000074695A2 (en) | 1999-06-03 | 2000-05-31 | Tanacetum parthenium extract |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20015867D0 NO20015867D0 (no) | 2001-11-30 |
| NO20015867L NO20015867L (no) | 2001-11-30 |
| NO328245B1 true NO328245B1 (no) | 2010-01-18 |
Family
ID=11383110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20015867A NO328245B1 (no) | 1999-06-03 | 2001-11-30 | Ekstrakter av Tanacetum parthenium og farmasoytiske og kosmetiske sammensetninger inneholdende ekstraktene. |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US6224875B1 (it) |
| EP (1) | EP1181030B1 (it) |
| JP (1) | JP4712258B2 (it) |
| KR (1) | KR100727121B1 (it) |
| CN (1) | CN1265814C (it) |
| AT (1) | ATE249232T1 (it) |
| AU (1) | AU769365B2 (it) |
| CA (1) | CA2375910C (it) |
| CZ (1) | CZ301703B6 (it) |
| DE (1) | DE60005174T2 (it) |
| DK (1) | DK1181030T3 (it) |
| ES (1) | ES2206251T3 (it) |
| HK (1) | HK1046245B (it) |
| HU (1) | HU228799B1 (it) |
| IL (2) | IL146841A0 (it) |
| IT (1) | IT1312342B1 (it) |
| NO (1) | NO328245B1 (it) |
| PL (1) | PL197514B1 (it) |
| PT (1) | PT1181030E (it) |
| RU (1) | RU2241475C2 (it) |
| SK (1) | SK285014B6 (it) |
| WO (1) | WO2000074695A2 (it) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030003170A1 (en) * | 2000-06-02 | 2003-01-02 | Theresa Callaghan | Method for the topical treatment and prevention of inflammatory disorders and related conditions using extracts of feverfew (Tanacetum parthenium) |
| US7547456B2 (en) * | 2001-03-16 | 2009-06-16 | Johnson & Johnson Consumer Companies, Inc. | Composition containing feverfew extract and use thereof |
| US20030077343A1 (en) * | 2001-03-16 | 2003-04-24 | Martin Katharine M. | Composition containing feverfew extract and use thereof |
| US20040086579A1 (en) * | 2002-11-05 | 2004-05-06 | Higgins James W. | Dietary supplement comprising parthenolide |
| US7192614B2 (en) | 2002-11-05 | 2007-03-20 | Gelstat Corporation | Compositions and methods of treatment to alleviate or prevent migrainous headaches and their associated symptoms |
| US20040247705A1 (en) * | 2003-06-06 | 2004-12-09 | Roberts Stephen C. | Transdermal compositions and methods of treatment to alleviate or prevent migrainous headaches and their associated symptoms |
| US20040247706A1 (en) * | 2003-06-06 | 2004-12-09 | Roberts Stephen C. | Transdermal dietary supplement comprising parthenolide |
| WO2005025586A1 (en) * | 2003-09-12 | 2005-03-24 | Access Business Group International Llc | Cytokine modulators and related method of use |
| US7758902B2 (en) * | 2003-09-12 | 2010-07-20 | Access Business Group International Llc | Cytokine modulators and related methods of use |
| US7758903B2 (en) | 2003-09-12 | 2010-07-20 | Access Business Group International Llc | Cytokine modulators and related methods of use |
| US20050186269A1 (en) * | 2004-02-25 | 2005-08-25 | Udell Ronald G. | Stabilized feverfew formulations |
| AU2013201510B2 (en) * | 2006-02-21 | 2015-07-16 | Isp Investments Inc. | Parthenolide Free Bioactive Ingredients from Feverfew (Tanacetum Parthenium) and Processes for their Production |
| CA2643255A1 (en) | 2006-02-21 | 2007-08-30 | Integrated Botanical Technologies, Llc | Parthenolide free bioactive ingredients from feverfew (tanacetum parthenium) and processes for their production |
| US20120089232A1 (en) | 2009-03-27 | 2012-04-12 | Jennifer Hagyoung Kang Choi | Medical devices with galvanic particulates |
| CN102781406B (zh) | 2010-03-01 | 2015-07-08 | 强生消费者公司 | 具有理想的整体颜色的护肤组合物 |
| CN103524520B (zh) * | 2013-09-25 | 2015-12-09 | 中国人民解放军第四军医大学 | 一种从植物原料中提取小白菊内酯的方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1270843A (en) * | 1982-05-19 | 1990-06-26 | Edward Stewart Johnson | Sesquiterpene lactones |
| GB9100581D0 (en) * | 1991-01-11 | 1991-02-27 | Rhodes Technology | Method for the extraction of sesquiterpene lactones |
| DE4202657C2 (de) * | 1992-01-31 | 1995-10-12 | Schaper & Bruemmer Gmbh | Pharmazeutisch wirksame Zusammensetzung aus Tanacetum parthenium sowie Verfahren zu deren Extraktion und mit der pharmazeutisch wirksamen Zusammensetzung hergestelltes Arzneimittel |
| FR2695931B1 (fr) * | 1992-09-24 | 1994-10-28 | Madeca | Procédé pour l'obtention de lactone sesquiterpénique de parthénolide, et préparation thérapeutique contenant un tel produit pour le traitement de la migraine. |
| WO2000074699A1 (en) * | 1999-06-03 | 2000-12-14 | Johnson & Johnson Consumer France Sas | Extracts of feverfew (tanacetum parthenium) against inflammatory disorders |
-
1999
- 1999-06-03 IT IT1999MI001244A patent/IT1312342B1/it active
- 1999-08-27 US US09/385,513 patent/US6224875B1/en not_active Expired - Lifetime
-
2000
- 2000-05-31 HU HU0201258A patent/HU228799B1/hu not_active IP Right Cessation
- 2000-05-31 DK DK00940292T patent/DK1181030T3/da active
- 2000-05-31 CN CNB008082944A patent/CN1265814C/zh not_active Expired - Fee Related
- 2000-05-31 RU RU2001132587/15A patent/RU2241475C2/ru not_active IP Right Cessation
- 2000-05-31 PT PT00940292T patent/PT1181030E/pt unknown
- 2000-05-31 ES ES00940292T patent/ES2206251T3/es not_active Expired - Lifetime
- 2000-05-31 JP JP2001501229A patent/JP4712258B2/ja not_active Expired - Fee Related
- 2000-05-31 CA CA2375910A patent/CA2375910C/en not_active Expired - Fee Related
- 2000-05-31 AT AT00940292T patent/ATE249232T1/de active
- 2000-05-31 EP EP00940292A patent/EP1181030B1/en not_active Expired - Lifetime
- 2000-05-31 PL PL352107A patent/PL197514B1/pl unknown
- 2000-05-31 AU AU55272/00A patent/AU769365B2/en not_active Ceased
- 2000-05-31 IL IL14684100A patent/IL146841A0/xx active IP Right Grant
- 2000-05-31 KR KR1020017015367A patent/KR100727121B1/ko active IP Right Grant
- 2000-05-31 CZ CZ20014304A patent/CZ301703B6/cs not_active IP Right Cessation
- 2000-05-31 SK SK1748-2001A patent/SK285014B6/sk not_active IP Right Cessation
- 2000-05-31 DE DE60005174T patent/DE60005174T2/de not_active Expired - Lifetime
- 2000-05-31 WO PCT/EP2000/004976 patent/WO2000074695A2/en active IP Right Grant
-
2001
- 2001-03-13 US US09/804,037 patent/US6479080B2/en not_active Expired - Lifetime
- 2001-11-29 IL IL146841A patent/IL146841A/en not_active IP Right Cessation
- 2001-11-30 NO NO20015867A patent/NO328245B1/no not_active IP Right Cessation
-
2002
- 2002-10-30 HK HK02107846.9A patent/HK1046245B/zh not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Duwiejua et al. | Anti-inflammatory activity of resins from some species of the plant family Burseraceae | |
| NO328245B1 (no) | Ekstrakter av Tanacetum parthenium og farmasoytiske og kosmetiske sammensetninger inneholdende ekstraktene. | |
| Lino et al. | Analgesic and antiinflammatory activities of Justicia pectoralis Jacq and its main constituents: coumarin and umbelliferone | |
| AU733601B2 (en) | Therapeutic composition and method for treating skin using centipeda cunninghami extract | |
| CH686556A5 (de) | Verfahren zur Herstellung von pestizidarmen Wirkstoffkonzentraten aus Pflanzen. | |
| DD247567A7 (de) | Verfahren zur herstellung bon biologisch aktiven polysacchariidkonzentraten und diese enthaltenden arzneimittelpraeparaten | |
| NO320407B1 (no) | Farmasoytiske og kosmetiske antiakneformuleringer inneholdende planteekstrakter (Krameria Triandra eller Mesua Ferrea) | |
| RU2126261C1 (ru) | Препарат из crataegus и фармацевтический состав для предотвращения внезапной смерти в результате остановки сердца и вызванных реперфузией сердечно-сосудистых поражений | |
| Patrick-Iwuanyanwu et al. | Pelagia Research Library | |
| FR2922110A1 (fr) | Utilisation d'un produit puissant extrait de rhizomes de zingiber officinale dans le traitement d'une maladie associee a helicobacter pylori | |
| EP2207559A2 (en) | Wound-healing agent containing momordicae semen extract | |
| Mamillapalli et al. | A detailed investigation of phytochemical, biological and commercial utilization of horse tail tree Casuarina equisetifolia | |
| Andhale et al. | PHARMACOLOGICAL REVIEW ON FICUS BENGALENSIS | |
| GB2335919A (en) | A method of producing high anti-inflammatory activity extracts from harpagophytum procumbens | |
| DE19732822C2 (de) | Soja-Extrakt, dessen Herstellungsverfahren und diesen enthaltende pharmazeutische Zusammensetzungen und deren Verwendung für die Prävention oder Behandlung von Alkoholismus | |
| WO1992021357A1 (de) | Pflanzliche dick- und/oder trockenextrakte | |
| KR20230023744A (ko) | 오에노테인 b 함량이 높은 에필로븀속 식물의 추출물을 제조하는 방법 | |
| KR20030021714A (ko) | 독성이 없이 추출된 생약추출물이 복합처방된 생약조성물과 그 제조방법 | |
| Dalal | Effect of Wedelolactone on CCl4 Induced Liver Damage | |
| Gururaja | A Review on Ethnopharmacology of Tectona grandis | |
| Sarkar | Bhringraj: A Pharmaceutical Treasure Trove |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |